PEER-REVIEWED ARTICLES, REPORTS, OPINION-EDITORIALS AND BLO

• Opinion Editorial: For the Trump drug plan to succeed, he'll have to get rid of rebates. Boston Business Journal, June 2025, William Smith and Robert Popovian. https://www.bizjournals.com/boston/news/2025/06/10/for-trump-drug-plan-to-succeed-he-mustkill-rebates.html 
• Report: Enhancing Adult Vaccine Uptake: Challenges in Shared Clinical Decision Making and Risk-Based Recommendations. Global Healthy Living Foundation, March 2025, Robert Popovian. https://ghlf.org/issues/vaccines/enhancing_adult_vaccine_uptake/ 
• Report: IQVIA Institute Human Data Sciences and Global Healthy Living Foundation, Assessing the Impact of State Pharmacist Vaccination Authority on Vaccine Uptake in the U.S., An Analysis of State-Level Policies and Adult Vaccination Rates, IQVIA Report, February 2025. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-impact-of-state-pharmacist-vaccination-authority-on-vaccine-uptake-in-the-us
• Report: How PBMs Work: A Primer. Pioneer Institute, January 2025, William Smith and Robert Popovian. https://pioneerinstitute.org/wp-content/uploads/PNR-598-PBM-final-01092025.pdf 
• Opinion Editorial: Inflation Reduction Act Price Controls and the 340B Program. Real Clear Health, December 2024,  William Smith and Robert Popovian https://www.realclearhealth.com/blog/2024/12/06/inflation_reduction_act_price_controls_and_the_340b_program_1076957.html
• Sydor AM, Rivera E, Popovian R. Could the Inflation Reduction Act Maximum Fair Price Hurt Patients? JHEOR. 2024;11(2):154-160. doi:10.36469/001c.125251 https://jheor.org/article/125251 
• Opinion Editorial: Pharmacy price-setting boards help big business, not patients. Baltimore Sun, September 2024, Robert Popovian. https://www.baltimoresun.com/2024/09/06/pharmacy-price-setting-boards-help-big-business-not-patients-guest-commentary/ 
• Report: Policy Proposals to Achieve Long-term Sustainability of Infused Biosimilars in the U.S. Summary Highlights from a Multi-Stakeholder Virtual Roundtable. IQVIA Institute for Human Data Science. https://cutt.ly/xeCYmxpJ 
• Opinion Editorial: The 340B Program is Costing Taxpayers Billions. Inside Sources, September 2024, William Smith and Robert Popovian. https://dcjournal.com/the-340b-program-is-costing-taxpayers-billions/ 
• Opinion Editorial: Health care profiteers skimming funds meant for poor. THE CAP TIMES MADISON, August 2024, Robert Popovian. https://captimes.com/opinion/guest-columns/opinion-health-care-profiteers-skimming-funds-meant-for-poor/article_4e3e1bc8-5436-11ef-99fc-130d9a9caf59.html 
• Report: Challenges To Vaccine Access for High-Risk Chronic Disease Adults: Real-World Experience Study and Policy Recommendations. Global Healthy Living Foundation, June 2024, Robert Popovian.   https://ghlf.org/issues/vaccines/challenges_vaccine_access/
• Opinion Editorial: Misguided Proposals Threaten Innovation, Access to Diabetes Medicines. Inside Sources, July 2024, Robert Popovian and William Smith. https://dcjournal.com/misguided-proposals-threaten-innovation-access-to-diabetes-medicines/ 
• Report: Challenges in Adult Vaccination: Policy Strategies for Sustaining Access and Supply. Global Healthy Living Foundation, May 2024, Robert Popovian. https://cutt.ly/AerE1kHd  
• Report: Impact of Inflation Reduction Act (IRA) on Pain Treatment Research. Pioneer Institute Paper, April 2024, William Smith and Robert Popovian. https://pioneerinstitute.org/news/study-finds-obstacles-to-search-for-opioid-substitute/ 
• Opinion Editorial: Pharmacists’ Crucial Role in Getting Vaccines into Arms. Governing, April 2024, Anita Patel, Robert Popovian and Vibhu Tewary. https://www.governing.com/policy/pharmacists-crucial-role-in-getting-vaccines-into-arms 
• Opinion Editorial: Pharmacy benefit managers, not Big Pharma, responsible for high drug prices. Boston Business Journal, April 2024, William Smith and Robert Popovian. https://www.bizjournals.com/boston/news/2024/04/15/commentary-gsk-flovent-decision-drug-pricing.html  
• Report: Removing Barriers to Pharmacy Vaccination: A Path to Better Health and Lower Health Care Costs. Global Healthy Living Foundation Report, April 2024, Popovian, Robert, Rivera, Esteban and Winegarden, Wayne. https://ghlf.org/wp-content/uploads/2024/03/Removing-Barriers-to-Pharmacy-Vaccination-A-Path-to-Better-Health-and-Lower-Health-Care-Costs.pdf
• Report: Value and Pricing Models for Gene Therapy Replacements:  The Current State of Affairs. Pioneer Institute Report, March 2024, Anne Sydor, William Smith and Robert Popovian. https://pioneerinstitute.org/wp-content/uploads/GeneTherapy-WP-3-24.pdf 
• Sydor AM, Bergin E, Kay J, Stone E, Popovian R. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion? JHEOR. 2024;11(1):86-93. doi:10.36469/001c.94544 https://jheor.org/article/94544 
• Opinion Editorial: Arizona must prioritize reform of federal safety net program. Arizona Capital Times and Arizona Daily Star, March 2024. https://azcapitoltimes.com/news/2024/03/18/arizona-must-prioritize-reform-of-federal-safety-net-program/ 
• Report: IQVIA Human Data Sciences and Global Healthy Living Foundation Trends in Adult Vaccination in the U.S., This report examines the impact of reimbursement to healthcare providers on influenza vaccination for the Medicaid fee-for-service population. IQVIA Report, February 2024. https://cutt.ly/CwMomUeE
• Opinion Editorial: Pharmacy Benefit Managers Are Not Conservative. National Review, February 2024, William Smith and Robert Popovian. https://www.nationalreview.com/2024/02/pharmacy-benefit-managers-are-not-conservative/ 
• Opinion Editorial: Bipartisan Reform Required to Turn Back the Clock on Outcomes of Federal Drug Discount Program. Real Clear Health, January 2024, William Smith and Robert Popovian. https://www.realclearhealth.com/blog/2024/01/26/bipartisan_reform_required_to_turn_back_the_clock_on_outcomes_of_federal_drug_discount_program_1007599.html 
• Chea S, Sydor AM and Popovian R.  Analysis of Drug Formulary Exclusions from the Patient's Perspective: 2023 Update. Health Science Journal, 2023. Vol. 17 No. S8:002. https://www.itmedicalteam.pl/articles/analysis-of-drug-formulary-exclusions-from-the-patients-perspective-update-2023-125203.html 
• Paper: Quantifying The Economic and Health Benefits From Rapid-Development COVID-19 Vaccines and Boosters. Progressive Policy Institute Report, January 2024, Michael Mandell, Robert Popovian and Wayne Winegarden. https://www.progressivepolicy.org/publication/quantifying-the-economic-and-health-benefits-from-rapid-development-covid-19-vaccines-and-boosters/ 
• Report: The Importance of Intellectual Property Protections for Patients. Pioneer Institute Report, October 2023, William Smith and Robert Popovian. https://pioneerinstitute.org/featured/pioneer-study-study-finds-patent-protections-fuel-biopharma-innovation-that-helps-patients/ 
• Opinion Editorial: Reinstating Co-Pays For Remote Patient Monitoring: A Barrier To Equitable Healthcare. Business Healthcare Today, September 2023, Benjamin Nowell and Robert Popovian. https://www.healthcarebusinesstoday.com/reinstating-co-pays-for-remote-patient-monitoring-a-barrier-to-equitable-healthcare/ 
• Opinion Editorial: Patients Need Faster Access To Approved FDA Vaccines. What Can We Do? Clinical Leader, August 2023. https://www.clinicalleader.com/doc/patients-need-faster-access-to-approved-fda-vaccines-what-can-we-do-0001 
• Opinion Editorial: The World’s Most Unethical Companies. Inside Sources, July 2023. https://dcjournal.com/the-worlds-most-unethical-companies/ 
• Opinion Editorial: Pharmacists are the solution for the lagging vaccination rates of seniors in the U.S. The Medium, June 2023. https://medium.com/@rpopovian/pharmacists-are-the-solution-for-the-lagging-vaccination-rates-of-seniors-in-the-u-s-a136fa054da9 
• Paper: Are we on the cusp of a new drug pricing program? Robert Popovian, Erin Delaney and Michael Mandel. The Medium, May 2023. https://progressivepolicyinstitute.medium.com/are-we-on-the-cusp-of-a-new-drug-pricing-paradigm-fdf611c009b3 
• Opinion Editorial: The Federal Government Fails on Hospital Charity Care. National Review. National Review, May 2023, William Smith and Robert Popovian. https://www.nationalreview.com/2023/05/the-federal-government-fails-on-hospital-charity-care/ 
• Report: Pioneer Institute: Out-of-Pocket Pirates: Spotlight on Accumulator & Maximizer. Pioneer Institute Report, April 2023, William Smith, Robert Popovian and Wayne Winegarden. https://cutt.ly/z5rSEZf  
• Opinion Editorial: A Federal Drug Discount Program for the Wealthy. Inside Sources, March 2023, William Smith and Robert Popovian. https://dcjournal.com/a-federal-drug-discount-program-for-the-wealthy/ 
• Opinion Editorial: Transparency Laws Are the First Step toward Creating a More Sustainable Health-Care System. National Review, Feb 2023, Robert Popovian and Catherine Windels. https://cutt.ly/BwwszYX2 
• Opinion Editorial: Getting vaccinated at pharmacies works: It could soon disappear. The Hill, January 2023, Kevin Ban and Robert Popovian. https://thehill.com/opinion/healthcare/3835860-getting-vaccinated-at-pharmacies-works-it-could-soon-disappear/ 
• Report: The Biosimilars Market in 2023: Important Trends and Milestones for Chronic Disease Patients, Patient Access and Affordability Project, January 2023.. https://accessandaffordability.org/wp-content/uploads/2023/01/2023-BioSimilars-Report-FINAL-01242023.pdf 
• Report: IQVIA Human Data Sciences and Global Healthy Living Foundation: Trends in Vaccine Administration in the United States, IQVIA Report, January 2023.. https://www.iqvia.com/insights/the-iqvia-institute/reports/trends-in-vaccine-administration-in-the-united-states 
• Opinion Editorial: It is Time for Policymakers to Protect Patients from Predatory Practices of Insurers and PBMs. Healthcare Business Today, January 2023, Robert Popovian and Louise Tharp. https://cutt.ly/ZwwsxpNU 
• Opinion Editorial: What is the Value of the Interchangeability Designation for a Biosimilar? Center for Biosimilars, November 2022, Robert Popovian, Wayne Winegarden and Peter Pitts https://www.centerforbiosimilars.com/view/contributor-what-is-the-value-of-the-interchangeability-designation-for-a-biosimilar-
• Schulthess, D., Bowen, H.P., Popovian, R. et al. The Relative Contributions of NIH and Private Sector Funding to the Approval of New Biopharmaceuticals. Therapeutic Innovation and Regulatory Science (2022). https://doi.org/10.1007/s43441-022-00451-8
• Pitts, Peter and Popovian, Robert, 340B and the Warped Rhetoric of Healthcare Compassion. Food and Drug Law Institute. September 2022. https://www.fdli.org/2022/09/340b-and-the-warped-rhetoric-of-healthcare-compassion/ 
• Opinion Editorial: PBMs are inflating the cost of generic drugs. They must be reined in, June 2022, STAT. https://www.statnews.com/2022/06/30/pbms-inflating-cost-generic-drugs/ 
• Opinion Editorial: Drug Pricing Bill Would Benefit Out-of-State Pharmacies, Not California Patients, June 2022, Today 90 News. https://www.today90.com/drug-pricing-bill-would-benefit-out-of-state-pharmacies-not-california-patients/ 
• Opinion Editorial: Propuesta de ley sobre precios de medicamentos beneficiaría a farmacias fuera del estado, no a pacientes en California, June 2022, La Opinion. https://laopinion.com/2022/06/27/propuesta-de-ley-sobre-precios-de-medicamentos-beneficiaria-a-farmacias-fuera-del-estado-no-a-pacientes-en-california/ 
• Opinion Editorial: Biopharmaceutical Innovation Should be Championed, June 2022, Inside Sources. https://insidesources.com/biopharmaceutical-innovation-should-be-championed/ 
• Opinion Editorial: Insurers and PBMs are Undermining Employee Health Benefits, June 2022, Healthcare Business Today, Robert Popovian and Louis Tharp. https://www.healthcarebusinesstoday.com/insurers-and-pbms-are-undermining-employee-health-benefits/ 
• Report: Trish, Erin and Van Nuys, Karen and Popovian, Robert, U.S. Consumers Overpay for Generic Drugs, USC Schaeffer Center for Health Policy Economics, May 31, 2022. https://healthpolicy.usc.edu/research/u-s-consumers-overpay-for-generic-drugs/ 
• Popovian, Robert, Sydor, Anne and Pitts Peter. Analysis of the Drug Formulary Exclusions from a Patient's Perspective. Health Sci J. Vol. 16 No. 3: 937. https://www.itmedicalteam.pl/articles/analysis-of-drug-formulary-exclusions-from-the-patients-perspective-111155.html 
• Opinion Editorial: The Out-of-Pocket Cost Ponzi Scheme, May 2022, Real Clear Health. https://www.realclearhealth.com/articles/2022/05/13/the_out-of-pocket_cost_ponzi_scheme_111340.html 
• Report: The Future of US Pricing and Market Access Environment, May 2022, First Word Report. https://www.firstwordreports.com/reportaction/596202198/Toc
• Robert Popovian, Wayne Winegarden, Esteban Rivera, and Kelly Gavigan, Accessibility of Adult Immunization in Pharmacies Compared to Physician Offices in Low-Income Communities. Journal of American Pharmacists Association. March 30, 2022. https://www.japha.org/article/S1544-3191(22)00094-2/fulltext 
• Opinion Editorial: Pharmacist-Administered Vaccinations Should Be Here to Stay, May 2022, Governing.  https://www.governing.com/now/pharmacist-administered-vaccinations-should-be-here-to-stay 
• Opinion Editorial: Biosimilar Adoption Will Help Achieve a Bipartisan Goal, April 2022, Center for Biosimilars. https://www.centerforbiosimilars.com/view/opinion-biosimilar-adoption-will-help-achieve-a-bipartisan-goal 
• Opinion Editorial: We Need to Avert the Next Public Health Disaster, Feb 2022, Inside Sources. https://insidesources.com/we-need-to-avert-the-next-public-health-disaster/ 
• Opinion Editorial: Benefit Design In Medicare Exacerbates Vaccine Access Inequity, Oct 2021, Outsourced Pharma https://www.outsourcedpharma.com/doc/benefit-design-in-medicare-exacerbates-vaccine-access-inequity-0001 
• Blog: Aiming Drug Price Reform at the Right Target, September 2021. https://www.progressivepolicy.org/blogs/aiming-drug-price-reform-at-the-right-target/ 
• Opinion Editorial: Vaccines are the future of health care, September 2021, The Hill. https://thehill.com/opinion/healthcare/572701-vaccines-are-the-future-of-health-care?rl=1 
• Pitts, Peter, Popovian, Robert and Winegarden, Wayne, Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent, Vol. 26 No. 2 (2021). Journal of Commercial Biotechnology. https://www.commercialbiotechnology.com/index.php/jcb/article/view/987 
• Opinion Editorial: Why Should We Rescue the Legislative Intent Of The BPCIA? Bioprocess, July 2021 https://www.bioprocessonline.com/doc/why-should-we-rescue-the-legislative-intent-of-the-bpcia-0001 
• Opinion Editorial: Waiving Covid-19 Vaccine Patents Is a Bad Idea and Sets a Dangerous Precedent, Town Hall, June 2021. https://townhall.com/columnists/peterpitts/2021/06/19/waiving-covid19-vaccine-patents-is-a-bad-idea-and-sets-a-dangerous-precedent-n2591208 
• Opinion Editorial: The US Drug Pricing System Needs to Be Fixed. Outsourced Pharma, June 2021. https://www.outsourcedpharma.com/doc/the-u-s-drug-pricing-system-needs-to-be-fixed-0001
• Popovian, Robert and Winegarden, Wayne, An Estimate of the Net Benefits from Prior Authorization Policies in the U.S., Vol. 15 No. 4: 833. Health Science Journal, https://www.itmedicalteam.pl/articles/an-estimate-of-the-net-benefits-from-prior-authorization-policies-in-the-us-106326.html 
• Opinion Editorial: Blurring the Lines between Medical Practice and Insurance Coverage. Healthcare Business Today, April 2021. https://www.healthcarebusinesstoday.com/blurring-the-lines-between-medical-practice-and-insurance-coverage/ 
• Opinion Editorial: No, Biologics are Not Natural Monopolies. Bioprocess, April 2021. https://www.bioprocessonline.com/doc/no-biologics-are-not-natural-monopolies-0001 
• Opinion Editorial: We Need Greater Transparency to Improve the U.S. Healthcare System. March 2021, Inside Sources. https://insidesources.com/we-need-greater-transparency-to-improve-the-u-s-healthcare-system/ 
• Opinion Editorial: The pandemic will end at your local pharmacy — if we let it. March 2021, Washington Examiner. https://www.washingtonexaminer.com/opinion/op-eds/the-pandemic-will-end-at-your-local-pharmacy-if-we-let-it 
• Winegarden, Wayne and Popovian, Robert, Reforming Rebate Contracting will Improve Drug Affordability, Special Issue 2, 006, Health Science Journal, https://www.itmedicalteam.pl/articles/reforming-rebate-contracting-willimprove-drug-affordability-106259.html
• Popovian, Robert, How to Ensure Equitable Access to Vaccines, Volume 11(6), December 2020, Journal of Vaccines and Vaccination. https://www.longdom.org/open-access/how-to-ensure-equitable-access-to-covid19-vaccine-59774.html
• Popovian, Robert and Hering, Dave, Enhance and Expand Access to Vaccines, Volume S5, November 2020, Journal of Vaccines and Vaccination. https://www.longdom.org/open-access/enhance-and-expand-access-to-vaccines.pdf 
• Winegarden, Wayne and Popovian, Robert, Reforming Rebates will Improve Drug Affordability. September 2020, Pacific Research Institute Paper. https://medecon.org/wp-content/uploads/2020/09/DrugRebates_F.pdf
• Blog: Reducing Costs, Enhancing Care through Utilization of Biosimilars, North Carolina Chamber of Commerce, September 2020. https://ncchamber.com/2020/09/24/reducing-costs-enhancing-care-through-utilization-of-biosimilars/ 
• Blog: Enhance and Expand Access to Vaccine, Healthcare Leadership Council, September 2020. https://www.hlc.org/post/enhance-and-expand-access-to-vaccines/ 
• Blog: Prior Authorization Changes Driven by the COVID-19 Pandemic, July 2020, Policy and Medicine, https://www.policymed.com/2020/07/prior-authorization-changes-driven-by-the-covid-19-pandemic.html
• Blog: Why Beating Covid-19 Will Require Strong Public Private Partnership. May 2020, Daily Signal. https://www.dailysignal.com/2020/05/27/why-beating-covid-19-will-require-strong-public-private-partnership/ 
• McCombs Jeff, Dang Richard, Popovian, Robert, Is the U.S. Ready to Quickly Vaccinate its Population Against COVID-19? May 2020, Schaeffer Institute Paper. https://healthpolicy.usc.edu/research/is-the-u-s-ready-to-quickly-vaccinate-its-population-against-covid-19/
• Blog: Underutilization of Prevention, Healthcare Leadership Council, March 2020. https://www.hlc.org/post/guest-post-the-underutilization-of-prevention/ 
• Interview: Life Science Leader, November 27, 2019, Biosimilar Competition Is Here To Stay In 2020. https://www.lifescienceleader.com/doc/biosimilar-competition-is-here-to-stay-in-0001 
• Report: McCombs Jeff, Myerson Rebecca, Xu Yifan, Popovian Robert, Value Based Contracting in Healthcare What is it and how can it be Achieved. June 2019, Schaeffer Institute Paper. https://healthpolicy.usc.edu/research/value-based-contracting-in-healthcare-what-is-it-and-how-can-it-be-achieved/ 
• McKinley Laura, Kelton John and Popovian Robert. Sowing confusion in the field: the interchangeable use of biosimilar terminology. January 2019. Current Medical Research and Opinion. https://pubmed.ncbi.nlm.nih.gov/30556742/ 
• Cazap Eduardo, Jacobs Ira, McBride Ali, Popovian, Robert and Sikora Karol. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. May 2018. The Oncologist, http://theoncologist.alphamedpress.org/content/early/2018/05/16/theoncologist.2017-0671 
• Interview: Managed Healthcare Executive, Jan 28, 2018, Pfizer VP Robert Popovian Talks Value-Based Reimbursement https://www.managedhealthcareexecutive.com/biosimilars/pfizer-vp-robert-popovian-talks-value-based-reimbursement 
• Opinion Editorial, Texas Tribune, Separating Fact From Fiction on Drug Costs, Trib Talk, Nov 1, 2017, https://www.tribtalk.org/2017/11/01/separating-fact-from-fiction-on-drug-costs/ 
• Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. September 29, 2017. Clinical Economics and Outcomes Research, https://www.ncbi.nlm.nih.gov/pubmed/29033595 
• Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG. Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. June 28, 2017. PharmacoEconomics, https://www.ncbi.nlm.nih.gov/pubmed/28660473 
• Boccia R, Jacobs I, Popovian R, G de Lima Lopes. Can Biosimilars Help Achieve the Goals of the U.S. Healthcare Reform? Cancer Management and Research. June 1, 2017, 9:197-205, https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/can-biosimilars-help-achieve-the-goals-of-us-health-care-reform/.
• James G. Stevenson, PharmD, Robert Popovian, PharmD, Ira Jacobs, MD, Susan Hurst, RPh, PhD, Lesley G. Shane, PharmD. Biosimilars, Practical Considerations for Pharmacists. Annals of Pharmacotherapy, February 2017, http://journals.sagepub.com/doi/full/10.1177/1060028017690743. 
• Cohen Hillel, Beydoun Donna, Chien David, Lessor Tracy, McCabe Dorothy, Muenzberg Michael, Popovian Robert and Uy Jonathan. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physician. Advances In Therapy. January 2017, Volume 33, Issue 12, pp 2160–2172
• Report: Academic Detailing: Pharma Fights Back, First Word Report, January 2012.
• Abstract: Nichol MB, Shi S, Knight TK, Popovian R, and Morita R. Impact of Market Forces on Statin persistence patterns in a California Medicaid population. Value In Health. 2004, Vol 7, No 3, page 334.
• Setter SM, Corbett C, Gates, B, Terriff C, Johns CA, Sclar DA, and Popovian R. Nonsteriodal Anti-inflammatory Drugs: The Need for Assessment and Education. Home Care Provider. 2001, VOL 6; PART 3, pages 100-105.
• Abstract: Setter SM, Corbett CF, Terriff CM, Gates BJ, Johns C, Broemeling L, Maccini D and Popovian R. Abstract - Knowledge of nonsteroidal anti-inflammatory drugs in at risk elders: effectiveness of individualized patient education. Pharmacotherapy. Volume 20 (10), 2000, page 1229.
• Abstract: Gerding, G, Carlson, J, Carter, C, Doak, M, Frederick, K and Popovian, R. Abstract – Treatment of Osteoarthritis and Rheumatoid Arthritis in a Long-term Care Setting. The Consultant Pharmacist. Volume 15 (9), 2000, page 933.
• Johnson, KA, Nichol MB, Popovian R and Liu G. Letter to the Editor: The Impact of Pharmaceutical Capitation to Primary Medical Groups on the Health Care Expenditures of Medicare HMO Enrollees. Journal of Managed Care Pharmacy. Volume 6 (1), January/February 2000, pages 8-9.
• Popovian R, Johnson, KA, Nichol MB and Liu G. The Impact of Pharmaceutical Capitation of Primary Medical Groups on the Health Care Expenditures of Medicare HMO Enrollees. Journal of Managed Care Pharmacy. Volume 5 (5), September/October 1999, pages 414-419.
• Niedermann MS, McCombs JS, Unger AN, Kumar A and Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clinical Therapeutics. Volume 21 (3), March 1999 1998, pages 576-591.
• Niedermann MS, McCombs JS, Unger AN, Kumar A and Popovian R. The Cost of Treating Community Acquired Pneumonia. Clinical Therapeutics. Volume 20 (4), July/August 1998, pages 820-837.
• Abstract: Popovian R, Hay, JW, Sung JCY and Jaresko GS,. Cost-effectiveness analyses of penicillin prophylaxis in dental procedures for prevention of infective endocarditis in mitral valve prolapse patients. Pharmacotherapy. Volume 17 (1), 1997, page 192.
• Abstract: Jaresko GS, Sung JC, Tajbakhsh-Werner G, Popovian R and Goldshtein G. Implementing an Interdisciplinary, pharmacy directed Enterobactor surveillance program. International Pharmaceutical Abstracts. Volume 33 (21), 1996, page 2245.
• Abstract: Jaresko GS, Popovian R, Nichol MB and Riley S. Factors influencing outcomes in patients with type I -lactamase producing gram negative bacteremia. Pharmacotherapy. Volume 15 (1), 1995, page 113.
• Popovian R, Bedikian A, Gill MA. Management of Diabetic Foot Ulcers. California Pharmacist. February 1993, pages 28-35.

MORNING CONSULT – OPINION EDITORIALS

• When Making Policy Decisions, Quality and Context of Data Should Be Scrutinized, November 2021 https://cutt.ly/yR1KuWq 
• We Should Not Lose Sight of the Upcoming Flu Season, September 2021 https://morningconsult.com/opinions/we-should-not-lose-sight-of-the-upcoming-flu-season/ 
• It is Time for Outcomes-Based Reimbursement for Biopharmaceuticals, July 2021 https://cutt.ly/5mLyGnw
• Innovation in Cancer Diagnostics Is the First Step in Ensuring Equity for All Patients, June 2021 https://cutt.ly/BnZN7Wk 
• Stop Failing Patients, May 2021 https://cutt.ly/qbGopom 
• We Can Address Vaccine Equity, April 2021 https://cutt.ly/LcEf9EL 
• President Biden’s Bipartisan Opportunity to Reduce Patients’ Drug Costs, March 2021 https://morningconsult.com/opinions/president-bidens-bipartisan-opportunity-to-reduce-patients-drug-costs/ 
• Five Policy Priorities to Ensure Equitable Access to a Covid-19 Vaccine, November 2020 https://morningconsult.com/opinions/five-policy-priorities-to-ensure-equitable-access-to-a-covid-19-vaccine/ 
• 12 Principles for Better Employer Stewardship of Health Care Benefit, October 2020 https://morningconsult.com/opinions/12-principles-for-better-employer-stewardship-of-health-care-benefit/
• Growing Body of Data on the Important Drug Cost Questions, July 2020 https://rb.gy/8lhuj4 
• Routine Vaccinations Shouldn’t be Another Victim of Covid-19, June 2020  https://morningconsult.com/opinions/routine-vaccinations-shouldnt-be-another-victim-of-covid-19/
• New Data Supports Adopting “Share The Savings” Reform, May 2020 https://morningconsult.com/opinions/new-data-supports-adopting-share-the-savings-reform/
• To Boost Adult Vaccination, Empower Pharmacists, March 2020 https://morningconsult.com/opinions/to-boost-adult-vaccinations-empower-pharmacists/
• Sustainable Solutions to Drug Shortages, February 2020 https://morningconsult.com/opinions/sustainable-solutions-to-drug-shortages/
• What Are Authorized Generics and Why Should You Care? January 2020 https://morningconsult.com/opinions/what-are-authorized-generics-and-why-should-you-care/
• Debunking the Myth of Who Funds Biomedical Innovation, December 2019 https://morningconsult.com/opinions/debunking-the-myth-of-who-funds-biomedical-innovation/
• Let The Facts Get in Way of a Get in The Way of Healthcare Spending Story, October 2019 https://morningconsult.com/opinions/let-facts-get-in-way-health-care-spending-story/
• We Still Need Rebate Reform, August 2019 https://morningconsult.com/opinions/we-still-need-rebate-reform/
• A Modern Payment Model for 21stCentury Cures, June 2019 https://morningconsult.com/opinions/modern-payment-model-21st-century-cures/
• Follow the Evidence on Premium Impact, May 2019 https://morningconsult.com/opinions/follow-evidence-premium-impact/
• Economic Analysis Fall Short When it Comes to Medicines’ Value, February 2019 https://morningconsult.com/opinions/economic-analysis-falls-short-when-comes-medicines-value/ 
• A Private-Sector Solution to Address Drug Spending That Everyone Is Ignoring, January 2019 https://morningconsult.com/opinions/private-sector-solution-address-drug-spending-that-everyone-ignoring/ 
• R&D Costs: Not a Simple Calculation, November 2018 https://morningconsult.com/opinions/rd-costs-not-simple-calculation/ 
• Anti-Clawback Laws — A Step in the Right Direction, September 2018 https://morningconsult.com/opinions/anti-clawback-laws-step-right-direction/ 
• Good Ideas Gone Bad in Health Care, June 2018 https://morningconsult.com/opinions/good-ideas-gone-bad-health-care/ 
• Comparing U.S. Healthcare Costs to Amounts in Other Countries Falls Short, May 2018 https://morningconsult.com/opinions/comparing-us-health-care-costs-amounts-other-countries-falls-short/ 
• We Can Address Vaccination Disparities through Policy Changes, Education, April 2018 https://morningconsult.com/opinions/we-can-address-vaccination-disparities-through-policy-changes-education/
• Time to Pass PBM Savings Back on to Patients, March 2018 https://morningconsult.com/opinions/time-to-pass-pbm-savings-on-to-patients/ 
• Reality, Not Rhetoric, of Drug Cost Trends, Feb 2018 https://morningconsult.com/opinions/reality-not-rhetoric-of-drug-cost-trends/ 
• Gene Therapy is a Game Changer, Nov 2017 https://morningconsult.com/opinions/gene-therapy-is-a-game-changer/ 
• Medical Treatments Must be Made by Providers and Patients, Oct 2017 https://morningconsult.com/opinions/medical-treatments-must-be-made-by-providers-and-patients/ 
• The Future of Manufacturing a Medicine in America, July 2017 https://morningconsult.com/opinions/future-manufacturing-medicine-america/ 
• Reauthorizing PDUFA is Key to a Healthier U.S. – May 2017 https://morningconsult.com/opinions/reauthorizing-pdufa-key-healthier-us/ 
• Real Facts Needed in Drug Price Policy Debate – April 2017 https://morningconsult.com/opinions/real-facts-needed-drug-price-policy-debate/ 
• Let the ‘Buyer Beware’ for Health Care Purchases – March 2017 https://morningconsult.com/opinions/let-buyer-beware-health-care-purchases/ 
• How to Achieve Value Based Reimbursement – Feb 2017 https://morningconsult.com/opinions/achieve-value-based-reimbursement/ 
• A Little Prevention Goes a Long Way to Reduce Costs – Dec 2016 https://morningconsult.com/opinions/little-prevention-goes-long-way-reduce-costs/ 
• The Facts Are Getting in the Way of a Good Story – Oct 2016 https://morningconsult.com/opinions/facts-getting-way-good-story/ 
• Five Important Questions on Health Care Costs – Sept 2016 https://morningconsult.com/opinions/five-important-questions-health-care-costs/ 
• In Drug Development, It’s About Time – July 2016 https://morningconsult.com/opinions/drug-development-time/ 
• No Substitute for Better Study to Protect Patients – June 2016 https://morningconsult.com/opinions/35143/ 
• Beyond Patent Life, Biosimilars Policy Requires a Nuanced Touch – May 2016 https://morningconsult.com/opinions/beyond-patent-life-biosimilars-policy-requires-nuanced-touch/ 
• The System is Working – A Not-So-Surprising Finding – April 2016 https://morningconsult.com/opinions/the-system-is-working-a-not-so-surprising-finding/ 
• Dedicated Scientists Driven to Discover Cures – March 2016 https://morningconsult.com/opinions/dedicated-scientists-driven-to-discover-cures/ 
• The Economics of Innovation – Feb 2016 https://morningconsult.com/opinions/the-economics-of-innovation/ 
• The Rest of the Research and Development Investment Story – Dec 2015 https://morningconsult.com/opinions/the-rest-of-the-research-and-development-investment-story/ 
• We Have Smart Phone and Soon Will Have Smart Cars, So Why Not Smart Evidence! – Oct 2015 https://morningconsult.com/opinions/we-have-smart-phones-and-soon-will-have-smart-cars-so-why-not-smart-evidence/ 
• Transparency for All Healthcare Costs and Outcomes – Sept 2015 https://morningconsult.com/opinions/transparency-for-all-healthcare-costs-and-outcomes/ 
• A Distinction That Makes a Difference in Healthcare – July 2015 https://morningconsult.com/opinions/a-distinction-that-makes-a-difference-in-healthcare/ 
• Sound Policy and Not Rhetoric Will Fix the Healthcare Cost Woes – June 2015 https://morningconsult.com/opinions/sound-policy-and-not-rhetoric-will-fix-healthcare-cost-woes/ 
• Proper Incentives for Proper Pain Treatment – May 2015 https://morningconsult.com/opinions/proper-incentives-for-proper-pain-treatment/ 
• Self-Care Leads to Better Health – April 2015 https://morningconsult.com/opinions/self-care-leads-to-better-health/ 
• Discrimination in Healthcare Insurance Coverage Needs to End – March 2015 https://morningconsult.com/opinions/discrimination-in-health-insurance-coverage-needs-to-end/ 
• It’s a Small World After All – Feb 2015 https://morningconsult.com/opinions/small-world/ 
• Cures Without Access No Cure At All – Jan 2015 https://morningconsult.com/opinions/cures-without-access-no-cure/ 
• A Spoonful of Medication Adherence Policy – Nov 2014 https://morningconsult.com/opinions/spoonful-medication-adherence-policy/ 
• Stepping Towards Failure – Oct 2014 https://morningconsult.com/opinions/columns-stepping-towards-failure/ 
• Partnership Needed to Access Real World Data – Sept 2014 https://morningconsult.com/opinions/partnership-needed-access-real-world-data/ 
• Paying for Value Not Volume – July 2014 https://morningconsult.com/opinions/paying-value-volume/ 
• Enabling US Biopharmaceutical Innovation – June 2014 https://morningconsult.com/opinions/enabling-u-s-biopharmaceutical-innovation/